Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Gefitinib-induced perforating dermatosis].

Montse Fernández-Guarino1, Isabel Aldanondo, Carmen González-García

  • 1Servicio de Dermatología, Hospital Ramón y Cajal, Madrid, España. montsefdez@msn.com

Actas Dermo-Sifiliograficas
|June 27, 2006
PubMed
Summary

Gefitinib, an EGFR-TK inhibitor, can cause skin issues. This report details a rare case of perforating dermatosis developing after gefitinib treatment for cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non-Small Cell Lung Cancer: Insights From the EVOKE-01 Study.

Cancer research communications·2026
Same author

First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.

Journal for immunotherapy of cancer·2026
Same author

Real-World Evidence That As-Needed Dosing with Bimekizumab in Patients with Psoriasis Is Safe and Effective over Time.

Journal of personalized medicine·2026
Same author

Gold-Induced Hypersensitivity Reaction After Fractional Radiofrequency Microneedling: A Case Report.

Contact dermatitis·2026
Same author

Memory Cells in Atopic Dermatitis: Paving the Way to Disease Modification.

International journal of molecular sciences·2026
Same author

Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemoradiotherapy.

Clinical and translational radiation oncology·2026

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Gefitinib is a targeted therapy inhibiting epidermal growth factor receptor tyrosine kinase (EGFR-TK).
  • EGFR-TK inhibitors are known to cause various cutaneous side effects.
  • Most skin reactions associated with these drugs are typically mild.

Observation:

  • A patient undergoing gefitinib treatment developed a rare skin condition.
  • The patient presented with symptoms indicative of perforating dermatosis.
  • This adverse event occurred during the course of gefitinib therapy.

Findings:

  • The case highlights a potential association between gefitinib and perforating dermatosis.
  • This specific dermatosis is an uncommon but significant adverse effect.

Related Experiment Videos

  • The findings underscore the importance of monitoring for dermatological reactions.

    • Implications:

    • Clinicians should be aware of this rare side effect of gefitinib.
    • Prompt recognition and management of cutaneous adverse events are crucial for patient care.
    • Further research may be needed to understand the mechanism linking gefitinib to perforating dermatosis.